Autoantibodies to the collagen-like region of C1q are strongly associated with classical pathway-mediated hypocomplementemia in systemic lupus erythematosus

被引:44
作者
FremeauxBacchi, V [1 ]
Weiss, L [1 ]
Demouchy, C [1 ]
Blouin, J [1 ]
Kazatchkine, MD [1 ]
机构
[1] UNIV PARIS 06,HOP BROUSSAIS,F-75014 PARIS,FRANCE
关键词
systemic lupus erythematosus; anti-C1q autoantibodies; complement activation;
D O I
10.1177/096120339600500309
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
We have investigated the presence of autoantibodies to the collagen-like region (CLR) of Clq and its relationship with classical pathway-dependent hypocomplementemia in patients with SLE. Antibodies to CLR/Clq were quantitated in the plasma of 113 unselected patients with SLE by ELISA, using purified CLR as antigen. Plasma concentration of C3, CH50 activity and C2 hemolytic activity were determined according to standard procedures. The prevalence of lgG antibodies to CLR/Clq in the study population was 33.6%. Plasma titers of anti-CLR/Clq autoantibodies showed a strong negative correlation with CH50 activity (p < 0.0001) and with plasma levels of C3 (p < 0.0001). Eighty-five percent of patients with severe complement consumption exhibited high titers of anti-CLR/Clq antibodies in plasma, independently of clinical disease activity. Anti-CLR/Clq antibodies were present in the plasma of 38% of patients with moderate classical pathway consumption and 14% of patients with no evidence of complement consumption. Analysis of sequential samples from six patients over a period of 18 to 24 months demonstrated that changes in CH50 activity mirrored those of the plasma titers of anti-CLR/Clq antibodies. Acquired hypocomplementemia through the classical pathway is strongly associated with the presence of anti-CLR/Clq autoantibodies in SLE. The results suggest that anti-CLR/Clq antibodies may perpetuate classical pathway activation, independently of clinical disease activity.
引用
收藏
页码:216 / 220
页数:5
相关论文
共 25 条
[1]
AGNELLO V, 1971, J EXP MED, V134, P228
[2]
ATKINSON JP, 1989, CLIN EXP RHEUMATO S3, V7, P95
[3]
COMPLEMENT-HUMAN HISTOCOMPATIBILITY ANTIGEN HAPLOTYPES IN C2 DEFICIENCY [J].
AWDEH, ZL ;
RAUM, DD ;
GLASS, D ;
AGNELLO, V ;
SCHUR, PH ;
JOHNSTON, RB ;
GELFAND, EW ;
BALLOW, M ;
YUNIS, E ;
ALPER, CA .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 67 (02) :581-583
[4]
INHERITED STRUCTURAL POLYMORPHISM OF THE 4TH COMPONENT OF HUMAN-COMPLEMENT [J].
AWDEH, ZL ;
ALPER, CA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (06) :3576-3580
[5]
DAHA MR, 1983, CLIN EXP IMMUNOL, V53, P541
[6]
HAUPTMANN G, 1993, IMMUNODEFICIENCIES, P253
[7]
JIANG HX, 1991, J IMMUNOL, V146, P2324
[8]
JIANG HX, 1992, J BIOL CHEM, V267, P25597
[9]
Kazatchkine M, 1985, TECHNIQUES COMPLEMEN
[10]
IMMUNE-COMPLEXES, COMPLEMENT, AND ANTI-DNA IN EXACERBATIONS OF SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE) [J].
LLOYD, W ;
SCHUR, PH .
MEDICINE, 1981, 60 (03) :208-217